Weekly Analysts’ Ratings Changes for Urogen Pharma (URGN)

Urogen Pharma (NASDAQ: URGN) recently received a number of ratings updates from brokerages and research firms:

• 7/17/2026 – Urogen Pharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Urogen Pharma had its price target raised by Oppenheimer Holdings, Inc. from $40.00 to $50.00. They now have an “outperform” rating on the stock.
• 7/15/2026 – Urogen Pharma had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $44.00 price target on the stock.
• 7/9/2026 – Urogen Pharma had its “buy” rating reaffirmed by UBS Group AG.
• 7/9/2026 – Urogen Pharma had its “buy” rating reaffirmed by HC Wainwright.
• 6/3/2026 – Urogen Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 6/2/2026 – Urogen Pharma had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider directly owned 119,763 shares in the company, valued at approximately $4,790,520. This trade represents a 7.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 25,222 shares of company stock worth $892,661. 4.80% of the stock is currently owned by company insiders.

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.